US8684591089
US8684591089
Supernus Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 718.952.000 | 661.817.000 | 8.6% |
| Cost of Revenue | 74.562.000 | 77.906.000 | 4.3% |
| Gross Profit | 644.390.000 | 583.911.000 | 10.4% |
| 681.254.000 | 508.355.000 | 34.0% | |
| Operating Income | -36.864.000 | 75.556.000 | 148.8% |
| Pretax Income | -49.030.000 | 97.870.000 | 150.1% |
| Net Income Common Stockholders | -38.550.000 | 73.865.000 | 152.2% |
| -- | -- | -- | |
| -- | -- | -- |